Regulatory Update

Missouri Law HB 2974 Speeds Licensing, Expands Telehealth Access

Kansas City, Mo. – September 17, 2026 -- Missouri Governor Mike Kehoe joined nonpartisan think tank United WE at its Kansas City headquarters on September 10 for a ceremonial signing of House Bill 2974, a law that shortens licensing wait times for out-of-state professionals and clarifies telehealth rules for providers with reciprocal Missouri licenses. The bill was formally signed on July 13 and took effect August 28.

HB 2974 resolves ambiguity blocking telehealth providers from treating Missouri patients

The law confirms that a health care provider granted a Missouri license based on an out-of-state credential is fully licensed in the state, including for delivering care to Missouri patients via telehealth. The previous statute, in place since 2018, had left that question unresolved.

Nutex Health Says Hackers Published Stolen Data, Faces Lawsuits

Houston – September 17, 2026 -- Nutex Health Inc. (NASDAQ: NUTX) disclosed that the unauthorized third party behind its previously reported cybersecurity breach has now published on its own website the data allegedly stolen from the healthcare operator's network.

Nutex confirms attacker posted stolen data online

The Houston-based company, which operates 28 hospital facilities across 12 states, said it first flagged unauthorized network activity in an September 17, 2026 Form 8-K filed with the Securities and Exchange Commission, updated on September 17, 2026. Nutex has engaged an independent cybersecurity response team and forensic experts, activated containment measures and notified law enforcement.

Experts Issue First Global Consensus on Type 1 Diabetes Screening

New York – September 17, 2026 -- A consensus paper published in Diabetologia establishes the first international framework for population-wide screening of type 1 diabetes (T1D), setting concrete age thresholds and testing protocols for clinical adoption.

Nearly 30 global experts define screening ages and intervals

The guidance, convened by Breakthrough T1D and developed by close to 30 international experts, recommends initial autoantibody screening for children aged 2-4 years. Children who test negative should be rescreened at ages 6-8 and again at 10-15, timed to align with routine preventative healthcare visits. Initial positive results require confirmation with a second test before diagnosis is made.

We Card Marks 31st Awareness Month as FDA Scrutiny Persists

Arlington, Va. – – September 17, 2026 -- The We Card Program is marking its 31st annual Awareness Month this September by pushing retailers nationwide to tighten age-verification training as FDA enforcement of tobacco, vapor and nicotine pouch sales remains a priority.

FDA enforcement pressure drives renewed retailer training push

David Spross, Executive Director of the National Association of Tobacco Outlets and a We Card board member, said September is the time to "ramp up and renew retailer compliance efforts" on federal, state and local requirements for selling age-restricted products.

Cardiol Therapeutics Files US$150M Shelf Prospectus, Expands OSC Disclosure

Toronto – September 17, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has filed a preliminary short form base shelf prospectus in Canada and a corresponding Form F-10 registration statement with the U.S. SEC, enabling the life sciences company to raise up to US$150 million over a 25-month period.

Shelf filing permits future issuance of shares, debt and warrants

The filings, made under the U.S./Canada Multijurisdictional Disclosure System, would allow Cardiol to offer Class A common shares, debt securities, warrants, subscription receipts, units, or combinations thereof, once a final receipt is issued and the Registration Statement becomes effective. No securities are being offered under this announcement, and the Company said there is no assurance an offering will occur.

Lode Gold Expands Fremont Drill Program With Four New Pads

Vancouver – September 17, 2026 -- Lode Gold Resources Inc. (TSXV: LOD) (OTCQB: LODFF) has expanded its drill program at the 100%-owned Fremont Gold Mine in Mariposa County, California, adding four new drill pads through an amendment to its existing Authorized Use Permit rather than seeking a new regulatory approval.

Four new pads target metallurgy, hydrogeology and untested ground

The expanded scope adds pads PT-J 011, PT-J 012, HGD-002 and HGD-003. Pads PT-J 011 and PT-J 012 will collect PQ-diameter metallurgical core samples to refine recovery mapping and geometallurgical domain modeling ahead of future feasibility work. Pads HGD-002 and HGD-003 are vertical hydrogeological holes designed for in-situ permeability testing and baseline hydrological monitoring required for mine planning.

Hikma's Epinephrine Nasal Spray Advances Through FDA, EU, UK Review

London – September 17, 2026 -- Hikma Pharmaceuticals PLC said regulators in the United States, Europe, and the UK have accepted for review its investigational epinephrine nasal spray, a needle-free treatment for anaphylaxis, with an additional filing lodged in Canada.

FDA accepts 505(b)(2) application for non-injectable anaphylaxis treatment

The US Food and Drug Administration has taken up a New Drug Application submitted under the 505(b)(2) pathway, which includes the required non-clinical and clinical data package supporting approval of the nasal spray for emergency anaphylaxis treatment.

Hagens Berman Probes IBM Over Q2 Mainframe Revenue Collapse

San Francisco – September 16, 2026 -- Shareholder rights firm Hagens Berman is investigating International Business Machines Corporation (NYSE: IBM) for potential securities law violations after CEO Arvind Krishna disclosed a Q2 2026 earnings shortfall on September 16, 2026 that wiped out over $68 billion in market capitalization in a single trading day, sending IBM shares down 25%.

IBM's Z mainframe business drove a sudden reversal from prior growth guidance

On September 16, 2026, IBM reported quarterly revenue gains of 15% in Infrastructure, 28% in Hybrid Infrastructure, and 51% in IBM Z, with management projecting constant-currency revenue growth of "5-plus percent" for 2026 and a similar growth rate for the second quarter. Executives at the time called it a "tremendous start" and a "record start" for the z17 mainframe, launched in April 2025 as IBM's flagship system for large-scale AI processing.

Obesity Drug Market Hits $16B as Lilly, Novo Face New Rivals

Las Vegas – – September 16, 2026 -- The obesity therapeutics market across the seven major markets was valued at approximately USD 16 billion in 2025 and is projected to grow at a 27% CAGR through 2036, according to DelveInsight, as a wave of next-generation candidates threatens to disrupt the Eli Lilly-Novo Nordisk duopoly.

Oral GLP-1 Therapies Accelerate Patient Uptake

Novo Nordisk's oral WEGOVY surpassed 5 million cumulative U.S. prescriptions within 30 weeks of launch, while Eli Lilly's oral FOUNDAYO (orforglipron) gained significant traction among patients initiating obesity treatment by mid-2026. Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said FOUNDAYO's once-daily oral formulation positions it for rapid uptake as a more convenient alternative to injectable therapies.

Claroty Public Sector Achieves CJIS Compliance With Fortreum

Arlington, Va. – September 16, 2026 -- Claroty Public Sector LLC's xDome for Government platform has achieved compliance with the FBI's Criminal Justice Information Services (CJIS) Security Policy, the company announced in partnership with cybersecurity advisory firm Fortreum.

Compliance targets protection of criminal justice data confidentiality and integrity

The CJIS certification confirms Claroty's cyber-physical systems (CPS) platform meets the FBI's security requirements for handling sensitive criminal justice information. Law enforcement and public safety agencies face mounting pressure to secure a growing base of connected and legacy infrastructure, including weapons platforms, building management systems, operational technology, and IoT devices, while limiting third-party and vendor risk.